Leuven, February 12, 2015 - ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that JETREA® (ocriplasmin) has gained approval in Argentina and Israel.

In both countries, JETREA® has been indicated for the treatment of adults with vitreomacular traction (VMT) including when associated with macular hole of diameter less than or equal to 400 microns.

If left untreated, VMT generally leads to significant visual distortion, deterioration in visual acuity, or even central blindness. With JETREA®, retina physicians in Israel and Argentina in the future will have access to the world's first and only pharmacological treatment option, allowing them to intervene earlier and potentially stopping the progression of this debilitating disease.

ThromboGenics' partner Alcon, which is commercializing JETREA® outside the US, will be responsible for the launch of the drug in Argentina and Israel.

distributed by